Generic HAART Triomune : d4T, 3TC, NVP — Competitive Intelligence Brief

Generic HAART Triomune : d4T, 3TC, NVP (Generic HAART Triomune : d4T, 3TC, NVP) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NRTI + NNRTI). Area: Infectious Disease / Virology.

marketed Antiretroviral combination therapy (NRTI + NNRTI) HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Generic HAART Triomune : d4T, 3TC, NVP (Generic HAART Triomune : d4T, 3TC, NVP) — University of KwaZulu. Triomune is a fixed-dose combination antiretroviral therapy that inhibits HIV reverse transcriptase and protease to suppress viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Generic HAART Triomune : d4T, 3TC, NVP TARGET	Generic HAART Triomune : d4T, 3TC, NVP	University of KwaZulu	marketed	Antiretroviral combination therapy (NRTI + NNRTI)	HIV reverse transcriptase
lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine	lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine	University of British Columbia	marketed	Antiretroviral combination therapy (protease inhibitor + non-nucleoside reverse transcriptase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
LPV/r + TDF/FTC or TDF/3TC	LPV/r + TDF/FTC or TDF/3TC	The HIV Netherlands Australia Thailand Research Collaboration	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease; HIV reverse transcriptase
Symtuza® (TAF/FTC/DRV/c)	Symtuza® (TAF/FTC/DRV/c)	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination (NRTI/INSTI class with protease inhibitor)	HIV reverse transcriptase, HIV protease, CYP3A4
Twice-daily ABC+3TC	Twice-daily ABC+3TC	Medical Research Council	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
AZT	AZT	Johns Hopkins Bloomberg School of Public Health	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase
tenofovir + emtricitabine + atazanavir-ritonavir	tenofovir + emtricitabine + atazanavir-ritonavir	Juan A. Arnaiz	marketed	Antiretroviral combination (NRTI + PI/r)	HIV reverse transcriptase, HIV protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NRTI + NNRTI) class)

1. GlaxoSmithKline · 2 drugs in this class
2. Clinical Trial Agency of HIV Study Group · 1 drug in this class
3. Hospital Clinic of Barcelona · 1 drug in this class
4. Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · 1 drug in this class
5. National Center for AIDS/STD Control and Prevention, China CDC · 1 drug in this class
6. Peking Union Medical College Hospital · 1 drug in this class
7. Sheba Medical Center · 1 drug in this class
8. Azienda Ospedaliera San Gerardo di Monza · 1 drug in this class
9. University of KwaZulu · 1 drug in this class